Jordan Silberman
Palo Alto, California, 94301, United States
NCT Number: NCT04609644
The Asthma Digital Study is a virtual, two-arm, randomized, controlled trial that will investigate the impact of digital tools on asthma symptom control, exacerbation frequency, healthcare utilization, and medical expenditures in adults with asthma.
Looking for future studies?
Notify Me18 year–64 year
All sexes
Interventional
Not applicable
Palo Alto, California, 94301, United States
The Asthma Digital Study is a virtual, two-arm, randomized, controlled trial that will investigate the impact of digital tools on asthma symptom control, exacerbation frequency, healthcare utilization, and medical expenditures. Adults with asthma will be randomized to the passive or active arm in a 1:1 ratio.
All participants will be sent two devices, at no cost-an Apple Watch and a Beddit Sleep Monitor. These are publicly available, commercial devices that have not been modified for this study.
The study will be administered largely through a customized version of CareEvolution's MyDataHelps app (the "Study App"). Access to the Study App will be provided to all participants. It will be used to administer informed consent and electronic patient reported outcome (ePRO) measures, and for other study purposes. Only active arm participants will have access to Study App features designed to support asthma self-management. These features include "smart nudges" based on device data, symptom and trigger tracking, evidence-based education, summaries of health metrics gathered from the Apple Watch and Beddit Sleep Monitor, in-app medication refill resources, as well as other resources.
The study duration is 2 years. Participants can keep using the Study App and devices after Year 1, though this is not required. Primary analyses will utilize Year 1 data only. During Year 2, data collection will continue where available, though fewer data will be collected because use of digital tools is not required during Year 2, and health coverage changes may cause loss of access to claims data.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Please see description of active study arm.
Time frame: 12 months before and after baseline
Sum of all allowed costs for emergency and hospital care, where asthma is specified as a diagnosis. Costs from the 12 months preceding baseline will be compared to costs from 12 months after baseline. Mean change in costs will be compared across arms.
Time frame: Baseline and 12-month time points
ACT change among all participants with baseline ACT score suggesting that asthma may be uncontrolled (ACT score of 19 or lower). Mean ACT change will be compared across arms.
Time frame: Active arm only: Baseline and months 1, 2, 3, 4, 5, 6, 8, 10, 12
Change from baseline among active arm participants with baseline ACT score suggesting that asthma may be uncontrolled (ACT score of 19 or lower).
Time frame: Active arm only: 2 weeks and months 2, 4, 6, 8, 10, 12
Validated PRO measure of medication adherence
Time frame: Active arm only: 2 weeks and months 2, 4, 6, 8, 10, 12
PRO measuring confidence in, and perceived importance of, asthma self-management
Time frame: Active arm only: Baseline and months 1, 3, 5, 8, 12
Validated PRO measure of asthma-associated work productivity impairment
Time frame: Active arm only: Baseline and months 1, 3, 5, 8, 12
Validated PRO measure of confidence in ability to manage general health
Time frame: Baseline and month 12
Adaptations of validated PRO measures
Time frame: Active arm only: Months 1-12
Measured using Study App
Time frame: Months 1-12; Months 13-24
Time frame: Months 1-12; Months 13-24
For details see: www.ncqa.org/hedis/measures/medication-management-for-people-with-asthma-and-asthma-medication-ratio/
Time frame: Months 1-12; Months 13-24
Proportion of days covered, measured using pharmacy claims
Time frame: Months 13-24
Computed in the same manner as the primary outcome, except that expenditures are computed for Year 2 rather than Year 1.
Time frame: Months 1-12; Months 13-24
Total allowed costs for all care associated with asthma, including pharmacy and other costs
Time frame: Months 1-12; Months 13-24
Total allowed costs for all claimed healthcare expenses
Time frame: Months 1-12; Months 13-24
Includes acute primary care visits, urgent care visits, emergency visits
Time frame: Active arm only: Months 1-12; Months 13-24
Frequencies of symptom tracking, trigger tracking, app opens
Time frame: Months 1-12; Months 13-24
Elevance Health
Industry
Digital Tools for Improved Awareness and Self-Management of Asthma in Adults
Acronym: ADS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07394127
Asthma, Asthma Chronic
Gümüşhane, Trabzon, Ordu, Giresun, Rize, Artvin, Gümüşhane, Turkey (Türkiye)
View Trial DetailsNCT01678222
Allergic Inflammation, Asthma
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT03937804
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03927820
Asthma, Bronchial Diseases
Nashville, Tennessee, United States
View Trial Details